MediLink Is Said to Weigh Licensing Deal Ahead of Potential IPO
MediLink Therapeutics Ltd. is exploring a licensing partnership to develop an antibody-drug conjugate with a global pharmaceutical company, according to people familiar with the situation.
MediLink is working with an adviser to sound out interest for cancer drug YL201, the people said, asking not to be identified because the deliberations are private. A deal could serve as a stepping stone toward an initial public offering, possibly in Hong Kong and as soon as 2026, the people said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
3 days ago
- Bloomberg
Biotech Firm MediLink Is Said to Hire Banks for Hong Kong IPO
MediLink Therapeutics Ltd. has hired China International Capital Corp., JPMorgan Chase & Co. and Morgan Stanley for a planned initial public offering in Hong Kong, according to people familiar with the matter. The Suzhou, China-based biotechnology company is seeking to raise more than $100 million in the IPO, the people said, asking not to be identified because the information isn't public.
Bloomberg
12-03-2025
- Bloomberg
MediLink Is Said to Weigh Licensing Deal Ahead of Potential IPO
MediLink Therapeutics Ltd. is exploring a licensing partnership to develop an antibody-drug conjugate with a global pharmaceutical company, according to people familiar with the situation. MediLink is working with an adviser to sound out interest for cancer drug YL201, the people said, asking not to be identified because the deliberations are private. A deal could serve as a stepping stone toward an initial public offering, possibly in Hong Kong and as soon as 2026, the people said.
Yahoo
09-01-2025
- Yahoo
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
SHANGHAI & SUZHOU, China & CAMBRIDGE, Mass., January 09, 2025--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a new strategic collaboration and worldwide license agreement with MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink") to use MediLink's TMALIN® antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab. Through this collaboration, Zai Lab further expands its global oncology pipeline with another potential first-in-class ADC targeting multiple solid tumors and addressing significant unmet medical needs. ZL-6201 has demonstrated encouraging preclinical data with an IND expected to be filed in 2025. "MediLink has built a differentiated proprietary ADC technology platform, and we are excited to broaden our global partnership," said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. "Building on the promising findings from our ongoing clinical trials for ZL-1310, this new collaboration demonstrates our continued focus on developing cancer therapies with ADC drugs and enriches our global oncology pipeline to address unmet medical needs. We look forward to working with MediLink to advance this compound into the clinic soon." "Zai Lab's strong commitment to innovation and proven track record of global development impressed us through our existing collaboration," said Tony Xue, PhD, CEO at MediLink. "This new partnership further validates our technology and enhances our strategic partnership. We believe our collaboration with Zai Lab will bring this innovative therapy to patients worldwide." About LRRC15 Leucine-rich repeat-containing protein 15 (LRRC15) is a type I transmembrane protein involved in cell-cell and cell-extracellular matrix (ECM) interactions. It is overexpressed in various mesenchymal tumors such as sarcoma, glioblastoma and melanoma, where it promotes tumor metastasis. Additionally, LRRC15 is upregulated in cancer-associated fibroblasts (CAFs) across various cancer types, contributing to immune-excluded and immune-suppressive tumor microenvironment (TME). This makes LRRC15 an appealing target for cancer therapy. About Zai Lab in ADC Zai Lab is building a portfolio of potential first- and/or best-in-class ADCs around the world. In addition to this next-generation ADC, the company has one near to commercial stage asset TIVDAK (tisotumab vedotin) and two next-generation ADC programs, ZL-1310 and ZL-6301, with exclusive worldwide rights. ZL-1310, a potential first-in-class ADC, is an investigational DLL3-targeted ADC being developed in a Phase 1 trial. Zai Lab presented encouraging efficacy and safety results for ZL-1310 from the ongoing Phase 1 study in patients with recurrent extensive-stage small cell lung cancer (SCLC) at the 2024 EORTC-NCI-AACR (ENA) Annual Symposium. About Zai Lab Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious diseases, and neuroscience. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide. For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit or follow us at Zai Lab Forward-Looking Statements This press release contains forward-looking statements relating to our future expectations, plans, and prospects, for Zai Lab, including, without limitation, statements relating to our prospects and plans for developing and commercializing next generation ADCs, the potential benefit of ADCs, and the potential treatment of solid tumors. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "possible," "potential," "will," "would," and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of our clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Our SEC filings can be found on our website at and on the SEC's website at Trademarks All trademarks and registered trademarks referenced within are property of their respective owners. View source version on Contacts For more information, please contact: Investor Relations: Christine Chiou / Lina Zhang+1 (917) 886-6929 / +86 136 8257 / Media:Shaun Maccoun / Xiaoyu Chen+1 857 270 8854 / +86 185 0015 /
